COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention

Author： Ballinger A.   Smith G.  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.1, 2001-01, pp. : 31-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Selective COX-2 inhibitors vs NSAIDs discussed

By  

Inpharma, Vol. 1, Iss. 1341, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

NSAIDs and Gastrointestinal Cancer Prevention

By Jolly K.  

Drugs, Vol. 62, Iss. 6, 2002-01 ,pp. : 945-956

Adis International

Access to resources Recommend Favorite

COX-2 inhibitors: lower risk of pancreatitis than other NSAIDs

By  

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Gastrointestinal Safety of Selective COX-2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 8, Iss. 12, 2002-06 ,pp. : 1077-1089

Bentham Science Publishers

Access to resources Recommend Favorite

Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors

By Latimer Nicholas  

PharmacoEconomics, Vol. 29, Iss. 3, 2011-03 ,pp. : 225-237

Adis International

Access to resources Recommend Favorite